|
Q3 FY2026
As of Sep 30, 2026
|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalents | ||||||||||||
| Cash and cash equivalents | ||||||||||||
| Restricted cash | ||||||||||||
| Accounts receivable, net | ||||||||||||
| Inventory | ||||||||||||
| Due from Chromocell Corporation | ||||||||||||
| Deferred offering costs | ||||||||||||
| Prepaid expenses and other current assets | ||||||||||||
| Total current assets | ||||||||||||
| Property and equipment, net | ||||||||||||
| Operating lease right-of-use assets, net | ||||||||||||
| Intangible assets, net | ||||||||||||
| Goodwill | ||||||||||||
| Other assets | ||||||||||||
| Total assets | ||||||||||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||||||
| Accounts payable and accrued expenses | ||||||||||||
| Accounts payable | ||||||||||||
| Accrued expenses | ||||||||||||
| Nonrelated Party | ||||||||||||
| Related Party | ||||||||||||
| Total accrued expenses | ||||||||||||
| Investor Note, net of debt discount | ||||||||||||
| Accrued milestones - related party | ||||||||||||
| Related Party | ||||||||||||
| Total accrued milestones - related party | ||||||||||||
| Contingent consideration | ||||||||||||
| Operating lease liabilities, current portion | ||||||||||||
| Loan payable, net of debt discount | ||||||||||||
| Loan payable - related party, net of debt discount | ||||||||||||
| Due to Chromocell Corporation | ||||||||||||
| Deferred revenue, current portion | ||||||||||||
| Other liabilities | ||||||||||||
| Nonrelated Party | ||||||||||||
| Related Party | ||||||||||||
| Total other liabilities | ||||||||||||
| Total current liabilities | ||||||||||||
| Deferred income tax liability | ||||||||||||
| Operating lease liabilities, net of current portion | ||||||||||||
| Deferred revenue, net of current portion | ||||||||||||
| Convertible notes payable - related party | ||||||||||||
| Related Party | ||||||||||||
| Total convertible notes payable - related party | ||||||||||||
| Venture loan and security agreement, net | ||||||||||||
| Other long-term liabilities | ||||||||||||
| Nonrelated Party | ||||||||||||
| Related Party | ||||||||||||
| Total other long-term liabilities | ||||||||||||
| Liabilities | ||||||||||||
| Related Party | ||||||||||||
| Total liabilities | ||||||||||||
| STOCKHOLDERS’ EQUITY | ||||||||||||
| Preferred stock, value | ||||||||||||
| Common stock, value | ||||||||||||
| Additional paid in capital | ||||||||||||
| Accumulated other comprehensive income | ||||||||||||
| Accumulated deficit | ||||||||||||
| Stockholders' (deficit) equity | ||||||||||||
| Series A Preferred Stock | ||||||||||||
| Series C Preferred Stock | ||||||||||||
| Total stockholders' (deficit) equity | ||||||||||||
| Total liabilities and stockholders' equity |
Loading...